| Host |
Mouse |
| Klon |
361 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Lokalisation |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
6 ml |
Ready-to-use |
CE/IVD |
PDM569 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM95 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Lokalisation |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
1 ml |
Concentrate |
CE/IVD |
Z2395ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM95 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Lokalisation |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
7 ml |
Ready-to-use |
CE/IVD |
Z2395MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM95 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Lokalisation |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
0.5 ml |
Concentrate |
CE/IVD |
Z2395MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM95 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Lokalisation |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
0.1 ml |
Concentrate |
CE/IVD |
Z2395MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to aa 569-588 of human Nrf2 protein. |
| Lokalisation |
Nuclear, Cytoplasmic |
Nrf2 (TCF11)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
514-12504 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CH, DG, MS, RB, RT |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:300 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from C-terminal of human NSE. |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
514-3302 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CH, DG, MS, RB, RT |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:300 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from C-terminal of human NSE. |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
514-3304 |
-
|
| Host |
Mouse |
| Klon |
DBMM4.507 |
| Format |
Concentrate |
| Methode |
P |
| Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b/kappa |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
1 ml |
Concentrate |
CE/IVD |
MOB616 |
-
|
| Host |
Mouse |
| Klon |
DBMM4.507 |
| Format |
Concentrate |
| Methode |
P |
| Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b/kappa |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
0.1 ml |
Concentrate |
CE/IVD |
MOB616-01 |
-
|
| Host |
Mouse |
| Klon |
DBMM4.507 |
| Format |
Concentrate |
| Methode |
P |
| Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b/kappa |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
0.5 ml |
Concentrate |
CE/IVD |
MOB616-05 |
-
|
| Host |
Mouse |
| Klon |
DBMM4.507 |
| Format |
ready-to-use |
| Methode |
P |
| Positivkontrolle |
Pancreas, Cerebellum, or Pheochromocytoma |
| Verdünnung |
--- |
| Isotyp |
IgG2b/kappa |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
6 ml |
ready-to-use |
CE/IVD |
PDM616 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR006 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP054 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP054-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP054-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM24 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
1 ml |
Concentrate |
CE/IVD |
Z2351ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM24 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or brain. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
7 ml |
Ready-to-use |
CE/IVD |
Z2351MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM24 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
0.5 ml |
Concentrate |
CE/IVD |
Z2351MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM24 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Lokalisation |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
0.1 ml |
Concentrate |
CE/IVD |
Z2351MT |
-
|
|
Nuclear Protein in Testis |
| Host |
Rabbit |
| Klon |
ZR456 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
NUT carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
A peptide corresponding to human NUT proteinund aa1-100) of human Claudin18.2 protein |
| Lokalisation |
Nucleus |
NUT
|
Zeta Corporation |
ZR456 |
1 ml |
Concentrate |
RUO |
Z2810RL-R |
-
|
| Host |
Rabbit |
| Klon |
DBRRM7.36 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Testis |
| Verdünnung |
1:50-1:100 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB115R |
-
|
| Host |
Rabbit |
| Klon |
DBRRM7.36 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Testis |
| Verdünnung |
1:50-1:100 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB115R-01 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM7.36 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Testis |
| Verdünnung |
1:50-1:100 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB115R-05 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM7.36 |
| Format |
ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Testis |
| Verdünnung |
--- |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Lokalisation |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD115R |
-
|
| Host |
Rabbit |
| Klon |
ZR227 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
B-cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
| Lokalisation |
Nuclear |
OCT-2
|
Zeta Corporation |
ZR227 |
0.1 ml |
Concentrate |
CE/IVD |
Z2708RT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM90 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
B-cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
| Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
1 ml |
Concentrate |
CE/IVD |
Z2400ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM90 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
B-cell lymphoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
| Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
7 ml |
Ready-to-use |
CE/IVD |
Z2400MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM90 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
B-cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
| Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
0.5 ml |
Concentrate |
CE/IVD |
Z2400MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM90 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
B-cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human OCT2 protein fragment (around aa 112-297) |
| Lokalisation |
Nucleus |
OCT-2 (Octamer Binding Transcription Factor 2)
|
Zeta Corporation |
ZM90 |
0.1 ml |
Concentrate |
CE/IVD |
Z2400MT |
-
|
| Host |
Mouse |
| Klon |
OCT4/6847R |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate Buffer pH 6.0 |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
| Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
1 ml |
Concentrate |
CE/IVD |
RMAB113 |
-
|
| Host |
Mouse |
| Klon |
OCT4/6847R |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate Buffer pH 6.0 |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
| Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
0.1 ml |
Concentrate |
CE/IVD |
RMAB113-01 |
-
|
| Host |
Mouse |
| Klon |
OCT4/6847R |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate Buffer pH 6.0 |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
| Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
0.5 ml |
Concentrate |
CE/IVD |
RMAB113-05 |
-
|
| Host |
Mouse |
| Klon |
OCT4/6847R |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate Buffer pH 6.0 |
| Positivkontrolle |
Seminoma |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
BALB/C mice injected with synthetic peptide of human OCT-3/4 origin |
| Lokalisation |
Nuclear |
OCT-3/4
|
Diagnostic Biosystems |
OCT4/6847R |
6 ml |
ready-to-use |
CE/IVD |
RMPD113 |
-
|
| Host |
Rabbit |
| Klon |
ZR364 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
| Lokalisation |
Nuclea |
OCT-4
|
Zeta Corporation |
ZR364 |
1ml |
Concentrate |
CE/IVD |
Z2604RL |
-
|
| Host |
Rabbit |
| Klon |
ZR364 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
| Lokalisation |
Nuclear |
OCT-4
|
Zeta Corporation |
ZR364 |
7 ml |
ready-to-use |
CE/IVD |
Z2604RP |
-
|
| Host |
Rabbit |
| Klon |
ZR364 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
| Lokalisation |
Nuclea |
OCT-4
|
Zeta Corporation |
ZR364 |
0.5 ml |
Concentrate |
CE/IVD |
Z2604RS |
-
|
| Host |
Rabbit |
| Klon |
ZR364 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human OCT- 4/POU5F1 protein (exact sequence is proprietary) |
| Lokalisation |
Nuclea |
OCT-4
|
Zeta Corporation |
ZR364 |
0.1 ml |
Concentrate |
CE/IVD |
Z2604RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Seminom |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK017-05 |
-
|
| Host |
Mouse |
| Klon |
C-10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Seminoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
| Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2104ML |
-
|
| Host |
Mouse |
| Klon |
C-10 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Seminoma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
| Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2104MP |
-
|
| Host |
Mouse |
| Klon |
C-10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Seminoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
| Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2104MS |
-
|
| Host |
Mouse |
| Klon |
C-10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Seminoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Amino acids 1-134 of OCT-4 of human origin |
| Lokalisation |
Nucleus |
OCT-4 (Octamer Binding Transcription Factor 4)
|
Zeta Corporation |
C-10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2104MT |
-
|
| Host |
Rabbit |
| Klon |
ZR340 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
| Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
1 ml |
Concentrate |
CE/IVD |
Z2646RL |
-
|
| Host |
Rabbit |
| Klon |
ZR340 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
| Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
7 ml |
ready-to-use |
CE/IVD |
Z2646RP |
-
|
| Host |
Rabbit |
| Klon |
ZR340 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
| Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
0.5 ml |
Concentrate |
CE/IVD |
Z2646RS |
-
|
| Host |
Rabbit |
| Klon |
ZR340 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Astrocytoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
| Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
0.1 ml |
Concentrate |
CE/IVD |
Z2646RT |
-
|
| Host |
Mouse |
| Klon |
3G221 |
| Format |
Highly Purified |
| Methode |
EL, WB, IHC, FL |
| Isotyp |
Mouse |
| Verdünnung |
Bovine Osteonectin. |
Osteonectin/SPARC
|
Zytomed Systems GmbH |
3G221 |
100 µg |
Highly Purified |
RUO |
216-1000 |
-
|
| Host |
Rabbit |
| Klon |
EPR23001-88 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG |
| Lokalisation |
Cell membrane |
OX / CD134
|
Biocare Medical |
EPR23001-88 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3245G |
-
|
| Host |
Rabbit |
| Klon |
SP271 |
| Format |
Concentrate |
| Methode |
P, WB, FL |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Cervical Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human p14ARF protein |
| Lokalisation |
Nucleus |
p14ARF
|
Zytomed Systems GmbH |
SP271 |
0.5 ml |
Concentrate |
RUO |
501-5712 |
-
|